(Q42857015)

English

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

scientific article published on 14 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 November 2017

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial (English)

1 reference

Europe PubMed Central

8 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Catherine Stedman

3

object named as

Catherine A M Stedman

1 reference

Europe PubMed Central

8 November 2017

1

object named as

Edward J Gane

1 reference

Europe PubMed Central

8 November 2017

author name string

Stuart K Roberts

2

1 reference

Europe PubMed Central

8 November 2017

Peter W Angus

4

1 reference

Europe PubMed Central

8 November 2017

Brett Ritchie

5

1 reference

Europe PubMed Central

8 November 2017

Rob Elston

6

1 reference

Europe PubMed Central

8 November 2017

David Ipe

7

1 reference

Europe PubMed Central

8 November 2017

Peter N Morcos

8

1 reference

Europe PubMed Central

8 November 2017

Linda Baher

9

1 reference

Europe PubMed Central

8 November 2017

Isabel Najera

10

1 reference

Europe PubMed Central

8 November 2017

Tom Chu

11

1 reference

Europe PubMed Central

8 November 2017

Uri Lopatin

12

1 reference

Europe PubMed Central

8 November 2017

M Michelle Berrey

13

1 reference

Europe PubMed Central

8 November 2017

William Bradford

14

1 reference

Europe PubMed Central

8 November 2017

Mark Laughlin

15

1 reference

Europe PubMed Central

8 November 2017

Nancy S Shulman

16

1 reference

Europe PubMed Central

8 November 2017

Patrick F Smith

17

1 reference

Europe PubMed Central

8 November 2017

language of work or name

0 references

publication date

14 October 2010

1 reference

Europe PubMed Central

8 November 2017

1 reference

Europe PubMed Central

8 November 2017

376

1 reference

Europe PubMed Central

8 November 2017

1467-1475

1 reference

Europe PubMed Central

8 November 2017

9751

1 reference

Europe PubMed Central

8 November 2017

Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Projecting future complications of chronic hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Changing trends in hepatitis C-related mortality in the United States, 1995-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The global burden of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

HCV variability, the immune system and resistance to antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modeling HCV kinetics under therapy using PK and PD information

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961384-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)61384-0

1 reference

Europe PubMed Central

8 November 2017

1 reference

Europe PubMed Central

8 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42857015&oldid=2113537329"